Evaluation of the humoral response induced by BBIBP-CorV vaccine by determining neutralizing antibodies in peruvian healthcare personnel

Authors

DOI:

https://doi.org/10.17843/rpmesp.2021.384.9244

Keywords:

Neutralizing Antibodies, Vaccination, Immunity, COVID-19, SARS-CoV-2

Abstract

Objective. To determine the titer of antibodies against the receptor binding domain (RBD) of the spike protein (S) in health personnel between the 4th and 12th week after receiving the BBIBP-CorV vaccine (Sinopharm). Materials and methods. We included a total of 168 healthcare workers from two hospitals in the region, who complied with the complete Sinopharm vaccine schedule; serum antibodies were measured using the Elecsys® Anti-SARS-CoV-2 test. Results. All participants developed antibodies to the RBD domain. The lowest antibody titer level was 1.78 U/mL. Levels equal to or above 250 were found in 70 (41.7%) participants. The geometric mean was 82.6 (95% CI: 67.8-100.6). Women had higher antibody levels. Participants whose antibodies were measured between 4- and 7-weeks post-vaccination showed significantly higher antibody levels than patients whose antibody levels were measured between 10- and 12-weeks post-vaccination. Among patients with a history of COVID-19, antibody levels were
found to be at or above 250 U/mL in 88% of cases, compared to 6% among those without a history of COVID-19, (p<0.001). Conclusion. All participants immunized with BBIBPCorV vaccine were positive for antibodies against the SARS-CoV-2 spike protein RBD. The correlation between the titer level and protection against COVID-19, as well as the length of the protection provided by the vaccine, needs to be evaluated.

Downloads

Download data is not yet available.

Published

2021-12-22

How to Cite

1.
Soto A, Charca-Rodríguez F de M, Pareja-Medina M, Fernandez-Navarro M, Altamirano-Cáceres K, Sierra Chávez E, Raraz-Vidal J, Cabezudo-Pillpe N, Velarde-Rodríguez M, Alcántara-Díaz A. Evaluation of the humoral response induced by BBIBP-CorV vaccine by determining neutralizing antibodies in peruvian healthcare personnel. Rev Peru Med Exp Salud Publica [nternet]. 2021 Dec. 22 [cited 2023 Jun. 7];38(4):493-500. vailable from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/9244

Issue

Section

Original Article

Most read articles by the same author(s)

1 2 > >>